Phreesia, Inc. (NYSE:PHR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Phreesia, Inc. has received a consensus recommendation of "Moderate Buy" from fourteen brokerages, with twelve analysts rating the stock as a buy and one as a strong buy.
• The average twelve-month price target for Phreesia is $33.85, reflecting optimistic views from various research firms that have recently updated their ratings and target prices.
• Phreesia reported a quarterly revenue of $117.26 million, exceeding expectations, and managed to beat the earnings estimate with an EPS of $0.01.

Phreesia, Inc. (NYSE:PHR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $33.8462.

Several research firms have recently commented on PHR. Needham & Company LLC lifted their target price on Phreesia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, September 5th. JMP Securities lifted their target price on Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a research note on Monday, September 8th. Citigroup reissued an "outperform" rating on shares of Phreesia in a research note on Monday, September 8th. Piper Sandler lifted their target price on Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a research note on Friday, September 5th. Finally, KeyCorp lowered their target price on Phreesia from $35.00 to $32.00 and set an "overweight" rating for the company in a research note on Wednesday, October 8th.

Phreesia Stock Performance

Shares of NYSE:PHR opened at $22.23 on Friday. Phreesia has a twelve month low of $17.07 and a twelve month high of $32.76. The firm has a market cap of $1.33 billion, a PE ratio of -52.93 and a beta of 0.68. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The business has a fifty day moving average of $26.10 and a 200-day moving average of $25.99.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.08. The company had revenue of $117.26 million during the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.The business's revenue for the quarter was up 14.9% on a year-over-year basis. During the same period last year, the firm earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, equities research analysts predict that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Phreesia

In related news, insider Evan Roberts sold 3,761 shares of Phreesia stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total transaction of $87,556.08. Following the completion of the sale, the insider directly owned 726,837 shares of the company's stock, valued at $16,920,765.36. The trade was a 0.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Linetsky sold 1,064 shares of Phreesia stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $23.50, for a total value of $25,004.00. Following the sale, the insider directly owned 173,888 shares of the company's stock, valued at approximately $4,086,368. This trade represents a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 85,532 shares of company stock valued at $2,530,640 over the last quarter. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Phreesia

A number of institutional investors have recently made changes to their positions in the stock. BankPlus Trust Department grew its stake in shares of Phreesia by 883.4% during the third quarter. BankPlus Trust Department now owns 8,880 shares of the company's stock worth $209,000 after purchasing an additional 7,977 shares during the period. Capricorn Fund Managers Ltd acquired a new stake in shares of Phreesia during the third quarter worth $11,395,000. Inspire Investing LLC grew its stake in shares of Phreesia by 38.8% during the third quarter. Inspire Investing LLC now owns 19,169 shares of the company's stock worth $451,000 after purchasing an additional 5,358 shares during the period. Moody National Bank Trust Division lifted its holdings in Phreesia by 3.7% during the third quarter. Moody National Bank Trust Division now owns 119,599 shares of the company's stock worth $2,813,000 after acquiring an additional 4,282 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company's stock worth $2,872,000 after acquiring an additional 71,553 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.